Page last updated: 2024-11-05
n-lauroylethanolamine
Description
N-lauroylethanolamine (also known as lauroyl ethanolamide or LEA) is a naturally occurring fatty acid amide found in various tissues, including the brain, gastrointestinal tract, and immune system. It is synthesized in the body through the enzymatic acylation of ethanolamine with lauric acid. LEA exhibits diverse biological activities, including anti-inflammatory, analgesic, and neuroprotective effects. It has been shown to modulate the activity of cannabinoid receptors, which are involved in the regulation of pain, appetite, and mood. Research on LEA is driven by its potential therapeutic applications in conditions such as chronic pain, inflammation, and neurodegenerative disorders. Its anti-inflammatory properties make it a potential target for the development of new drugs for treating inflammatory diseases. LEA's ability to interact with cannabinoid receptors suggests its potential role in managing chronic pain and other neurological disorders. Further research is ongoing to investigate its precise mechanisms of action and its therapeutic potential.'
lauroylethanolamide: N-acylethanolamine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
N-(dodecanoyl)ethanolamine : An N-(long-chain-acyl)ethanolamine resulting from the formal condensation of the carboxy group of dodecanoic acid (myristic acid) with the amino group of ethanolamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 8899 |
| CHEMBL ID | 246914 |
| CHEBI ID | 85263 |
| SCHEMBL ID | 679082 |
| MeSH ID | M0238751 |
Synonyms (85)
| Synonym |
|---|
| 1:1 cocamide mea |
| n-(2-hydroxyethyl)dodecanamide |
| 142-78-9 |
| amisol lde |
| dodecanamide, n-(2-hydroxyethyl)- |
| NAE , |
| lauramide mea |
| rolamid cm |
| n-(2-hydroxyethyl)lauramide |
| amisol lme |
| lauroyl monoethanolamide |
| cyclomide lm |
| hsdb 5644 |
| 2-dodecanamidoethanol |
| steinamid l 203 |
| lauric acid monoethanolamide |
| vistalan |
| lauric acid monoethanolamine |
| einecs 205-560-1 |
| rewomid l 203 |
| comperlan lm |
| monoethanolamine lauric acid amide |
| lauric monoethanolamide |
| lauric ethylolamide |
| copramyl |
| n-lauroylethanolamine |
| stabilor cmh |
| ccris 4834 |
| lauric acid ethanolamide |
| lauridit lm |
| crillon lme |
| ultrapole h |
| lauric n-(2-hydroxyethyl)amide |
| laurylamidoethanol |
| laurylethanolamide |
| 68140-00-1 |
| chebi:85263 , |
| CHEMBL246914 |
| LMFA08040041 |
| lauroyl-ea |
| lauroyl-ethanolamine |
| n-(dodecanoyl)-ethanolamine |
| unii-098p2igt76 |
| 098p2igt76 , |
| lauryl ethanolamide |
| FT-0625582 |
| AKOS010638882 |
| SCHEMBL679082 |
| n-(2-hydroxyethyl)dodecanamide [hsdb] |
| lauramide mea [inci] |
| lauramide monoethanolamide |
| n-(dodecanoyl)ethanolamine |
| dodecanoyl ethanolamide |
| n-dodecanoylethanolamine |
| DS-2807 |
| ablumide lme |
| crillon l.m.e. |
| lauroylethanolamide |
| alkamide l-203 |
| mackamide lmm |
| stabilor c.m.h. |
| n-(2-hydroxyethyl)dodecaneamide |
| empilan lme (salt/mix) |
| lauramide-mea (1:1) |
| dodecanamide, n-2-hydroxyethyl- |
| incromide lcl |
| 1:1 lauramide mea |
| hartamide lmea |
| lauryl monoethanolamide |
| cocomonoethanolamide (salt/mix) |
| W-109078 |
| c14h29no2 |
| DTXSID5025493 |
| dodecylethanol amide |
| lauric acid monoethanolamide, aldrichcpr |
| mfcd00020561 |
| CS-W022897 |
| Q27158443 |
| nae 12:0 |
| A885101 |
| lauricacidmonoethanolamide |
| coconutoil monoethanolamide |
| SY110473 |
| EN300-7367571 |
| Z808715244 |
Drug Classes (2)
| Class | Description |
|---|
| N-(long-chain-acyl)ethanolamine | Any N-acylethanolamine in which the acyl group has a chain length of C12 or greater. |
| N-(saturated fatty acyl)ethanolamine | Any N-acylethanolamine in which the acyl group is derived from a saturated fatty acid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID307154 | Solubility in chloroform | 2007 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
| Synthesis of new plant growth regulator: N-(fatty acid) O-aryloxyacetyl ethanolamine. |
| AID307155 | Solubility in ethyl acetate solution | 2007 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
| Synthesis of new plant growth regulator: N-(fatty acid) O-aryloxyacetyl ethanolamine. |
| AID307156 | Solubility in ethanol | 2007 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
| Synthesis of new plant growth regulator: N-(fatty acid) O-aryloxyacetyl ethanolamine. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.52
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.52 (24.57) | | Research Supply Index | 2.48 (2.92) | | Research Growth Index | 5.00 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |